Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fisher & Paykel HealthcareASX:FPH -0.23%90 Cash-to-Debt is 3.16 as of Mar. 2026, which is 95% above its 10-year median of 1.62. GuruFocus rates ASX:FPH with a GF Score™ of 90/100 and a GF Value™ of A$36.77 (Fairly Valued). The stock has 3 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 60.4% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Fisher & Paykel Healthcare's cash to debt ratio for the quarter that ended in Mar. 2026 was 3.16.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Fisher & Paykel Healthcarecould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Fisher & Paykel Healthcare's Cash-to-Debt or its related term are showing as below:
ASX:FPH'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43 Med: 1.62 Max: 3.19
Current: 3.16
During the past 13 years, Fisher & Paykel Healthcare's highest Cash to Debt Ratio was 3.19. The lowest was 0.43. And the median was 1.62.
ASX:FPH's Cash-to-Debt is ranked better than 60.4% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs ASX:FPH: 3.16
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Fisher & Paykel Healthcare Cash-to-Debt Related Terms
Fisher & Paykel Healthcare Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:FPH vs ISRG, BDX, RMD: Cash-to-Debt Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a Cash-to-Debt of 3.16 as of Mar. 2026. This is 95% above median its historical median of 1.62. Over the past decade, Fisher & Paykel Healthcare's Cash-to-Debt has ranged from 0.43 to 3.19. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #333 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 39.6%.
Is Fisher & Paykel Healthcare's Cash-to-Debt too high?
Fisher & Paykel Healthcare's current Cash-to-Debt of 3.16 is 95% above median its 10-year median of 1.62. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 3.19. The Medical Devices & Instruments industry median Cash-to-Debt is 1.62. Fisher & Paykel Healthcare's value of 3.16 is 95.1% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #333 out of 841 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #333 out of 841 companies for Cash-to-Debt. This puts Fisher & Paykel Healthcare in the upper half of its industry. The industry median Cash-to-Debt is 1.62. Fisher & Paykel Healthcare's value of 3.16 is 95.1% above this benchmark. Historically, Fisher & Paykel Healthcare's own Cash-to-Debt has ranged from 0.43 to 3.19 over the past decade. While the company's 10-year median is 1.62 vs. the industry median of 1.62, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.62, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current Cash-to-Debt of 3.16 is 95.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Cash-to-Debt is 3.16, which is 95% above median its own 10-year median of 1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.77, compared to a current price of A$35.20 — trading 4.3% below its estimated fair value. The current Cash-to-Debt is 3.16, which is 95% above median its 10-year median of 1.62 and 95.1% above the Medical Devices & Instruments industry median of 1.62. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Cash-to-Debt is 3.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$35.20 is trading 4.3% below its estimated GF Value™ of A$36.77.
GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.
Key valuation signals for ASX:FPH:
Cash-to-Debt: 3.16 (95% above median its 10-year median of 1.62)
GF Value™: A$36.77 vs. price of A$35.20 (4.3% below fair value)
Industry Position: 95.1% above the Medical Devices & Instruments median (#333 of 841)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score
Get the complete analysis for ASX:FPH
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
